Bellevue Group AG Increases Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

Bellevue Group AG lifted its stake in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 4.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,205,464 shares of the company's stock after purchasing an additional 50,810 shares during the period. Bellevue Group AG owned about 2.41% of Immunocore worth $37,526,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IMCR. Primecap Management Co. CA boosted its holdings in shares of Immunocore by 3,841.6% in the 2nd quarter. Primecap Management Co. CA now owns 1,951,070 shares of the company's stock valued at $66,122,000 after buying an additional 1,901,570 shares in the last quarter. Armistice Capital LLC grew its holdings in Immunocore by 495.1% in the second quarter. Armistice Capital LLC now owns 976,000 shares of the company's stock worth $33,077,000 after purchasing an additional 812,000 shares during the last quarter. Millennium Management LLC increased its position in shares of Immunocore by 124.4% during the second quarter. Millennium Management LLC now owns 600,954 shares of the company's stock worth $20,366,000 after purchasing an additional 333,167 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Immunocore by 1,867.3% during the 2nd quarter. SG Americas Securities LLC now owns 160,358 shares of the company's stock valued at $5,435,000 after purchasing an additional 152,207 shares during the last quarter. Finally, Candriam S.C.A. boosted its position in shares of Immunocore by 65.8% in the 2nd quarter. Candriam S.C.A. now owns 313,423 shares of the company's stock worth $10,621,000 after purchasing an additional 124,417 shares in the last quarter. Institutional investors own 84.50% of the company's stock.

Immunocore Price Performance

Shares of NASDAQ:IMCR traded down $0.09 during midday trading on Friday, hitting $32.74. The company had a trading volume of 146,601 shares, compared to its average volume of 244,503. The business's 50-day simple moving average is $32.20 and its 200-day simple moving average is $36.62. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -34.46 and a beta of 0.72. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. Immunocore Holdings plc has a twelve month low of $29.72 and a twelve month high of $76.98.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.33) by $0.50. The firm had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business's revenue for the quarter was up 23.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.59) EPS. On average, research analysts predict that Immunocore Holdings plc will post -0.94 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Morgan Stanley reduced their target price on Immunocore from $80.00 to $74.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Guggenheim lowered shares of Immunocore from a "buy" rating to a "neutral" rating in a research report on Monday, October 7th. Oppenheimer reissued an "outperform" rating and set a $89.00 target price (up previously from $87.00) on shares of Immunocore in a research report on Friday, August 9th. Needham & Company LLC decreased their price target on shares of Immunocore from $78.00 to $71.00 and set a "buy" rating for the company in a report on Thursday, November 7th. Finally, UBS Group started coverage on Immunocore in a research report on Thursday, October 24th. They set a "sell" rating and a $24.00 price target on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Immunocore has a consensus rating of "Moderate Buy" and an average price target of $69.18.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.